Contact Regeneron Pharmaceuticals Customer Service

Regeneron Pharmaceuticals, Inc. is a science and technology company headquartered in Tarrytown, New York. It was founded by Leonard S. Schleifer, MD, Ph.D. in 1988. Regeneron specializes in drug discovery and development. The company focuses on the investigational treatment of a broad range of serious medical conditions including cancer, rheumatoid arthritis, cardiovascular, atopic dermatitis, and infectious diseases. Regeneron Pharmaceuticals is traded on NASDAQ under the ticker symbol of REGN. As for now, Regeneron has more than 20 product candidates in clinical development across multiple therapeutic areas including Covid-19. The company coronavirus vaccine candidate is also known as REGN-COV2 or REGEN-COV2 received Emergency Use Authorization from the U.S. Food and Drug Administration. Regeneron’s Covid-19 vaccine candidate is authorized for the treatment of mild to moderate COVID-19 in adults and children 12 years old. About 300,000 patients were involved in the program of the SARS-CoV-2 viral testing. The clinical trials of the REGN-COV2 Covid-19 vaccine candidate showed a substantial reduction of viral loads and improvement of clinical outcomes. Currently, coronavirus vaccine therapy is being investigated by a number of biotechnological companies including Moderna, Gilead Sciences, and Novavax to fight Covid-19 and ensure recovery.